Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3 Randomized, Double-Blind, Active Comparator, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Brief Summary: This is a comparative study of CP 690,550, Humira (adalimumab) and placebo on background methotrexate in patients with Rheumatoid Arthritis. The study is intended to provide evidence of the efficacy and safety of CP 690,550 when dosed 5 mg and 10 mg twice a day on background methotrexate in adult patients with moderate to severe Rheumatoid Arthritis. It is intended to confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that were observed in Rheumatoid Arthritis. An active comparator, adalimumab, is also included.


Options:
A: Arm Label: Part A: SAR 100 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 100 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 150 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: SAR 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part A: Placebo qw; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B Cohort 1: Non-selected Doses; Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Sarilumab, Drug: Methotrexate, Drug: Folic Acid | Arm Label: Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Placebo (for sarilumab), Drug: Methotrexate, Drug: Folic Acid | Intervention Type: DRUG; Name: Sarilumab; Assigned to Arm(s): Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Placebo (for sarilumab); Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 150 mg q2w, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2) | Intervention Type: DRUG; Name: Folic Acid; Assigned to Arm(s): Part A: Placebo qw, Part A: SAR 100 mg q2w, Part A: SAR 100 mg qw, Part A: SAR 150 mg q2w, Part A: SAR 150 mg qw, Part A: SAR 200 mg q2w, Part B Cohort 1: Non-selected Doses, Part B: Placebo q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 150 mg q2w (Cohort 1[Selected Dose]+Cohort 2), Part B: SAR 200 mg q2w (Cohort 1[Selected Dose]+Cohort 2)
B: Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: methotrexate | Arm Label: Tocilizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: placebo | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab + Methotrexate, Tocilizumab + Placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Tocilizumab + Placebo
C: Arm Label: 5mg; Type: EXPERIMENTAL; Interventions: Drug: CP 690,550 | Arm Label: 10 mg; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo Sequence 1; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Placebo Sequence 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Biologic TNFi | Intervention Type: DRUG; Name: CP 690,550; Assigned to Arm(s): 5mg | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 10 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo Sequence 2 | Intervention Type: BIOLOGICAL; Name: Biologic TNFi; Assigned to Arm(s): adalimumab
D: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001

Answer: C